Advanced Medicine

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.

Here’s why the Cell and Gene Therapy Catapult is excited about the potential of digital twin technology.

Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.

How can you ensure your gene therapy research won’t be slowed down by synthesis problems?

Sitting Down With… Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.

What lies ahead for the future of pharma? Dennis van Rooji gives his view.

Accelerating the progress of cell and gene therapies with decentralized trials and other innovative approaches.

Cell and Gene therapies have come a long way since the 1970s. Technology, combined with knowledge, will take them even further.

Jon Thomas, CEO of CIRM, discusses the evolution of stem cell research and the future of regenerative medicine in this interview.

We find out why Cas12l incorporated into a gene-writing system could help advance the field of gene editing.